Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 (PDE1) is a family of dual-specificity enzymes (comprising PDE1A, PDE1B, and PDE1C) that catalyze the hydrolysis of the intracellular second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into their inactive 5'-monophosphate forms. A unique feature of the PDE1 family is its activation by the calcium/calmodulin complex, which directly couples intracellular calcium signaling with cyclic nucleotide degradation. PDE1 is widely expressed in the brain, heart, vascular smooth muscle, and kidneys, playing a critical role in regulating vascular tone, cardiac contractility, neuronal plasticity, and cell proliferation. Dysregulation of PDE1 is implicated in several pathological conditions, including cardiovascular diseases (such as pulmonary arterial hypertension and heart failure), neurodegenerative and neuropsychiatric disorders (such as Parkinson's disease, Alzheimer's disease, and schizophrenia), and autosomal dominant polycystic kidney disease. Pharmacological inhibition of PDE1, using drugs like lenrispodun (ITI-214) and vinpocetine, prevents the breakdown of cAMP and cGMP, thereby enhancing downstream protein kinase A (PKA) and protein kinase G (PKG) signaling. This therapeutic strategy is being actively investigated to improve cognitive function, promote neuroprotection, and induce vasodilation in various clinical settings.
Inhibition of cAMP and cGMP hydrolysis, leading to increased intracellular levels of cAMP and cGMP and subsequent activation of protein kinase A (PKA) and protein kinase G (PKG) signaling pathways.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 (PDE1).